Rehabilitation equipment leader, venturing into surgical robots!
On February 26th, Shanghai-listed company Xiangyu Medical disclosed a significant strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful assembly of a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics.
According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, bringing together technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. The expertise covers core areas including mechanical design, algorithm development, hardware integration, and software systems. More notably, the team has years of experience in the development of rehabilitation equipment and robots, providing a solid foundation for technological breakthroughs.
At the same time, Xiangyu Medical is also accelerating its layout in the AI sector. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from parsing structured medical records to generating personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a 99% risk prediction accuracy rate and a 45% reduction in missed diagnoses. This technological accumulation may pave the way for the intelligent upgrade of medical robot products.
01
Having already established a presence in the rehabilitation medical device market, why has Xiangyu Medical chosen to enter the robotics track at this time? There are three strategic considerations behind this decision:
Currently, there is a significant imbalance between the supply and demand for rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation doctors. Additionally, traditional equipment heavily relies on manual operation. In the face of complex patient needs, such as those recovering from stroke or orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages and significantly improving treatment outcomes. Xiangyu Medical has chosen to enter the rehabilitation scene by focusing on
On February 26, Shanghai Stock Exchange-listed company Xiangyu Medical disclosed in its investor relations activity record that it had made a significant strategic move: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the entry of Xiangyu Medical, known for rehabilitation medical devices, into the field of medical robotics.
According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, bringing together technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology, with expertise covering core areas including mechanical design, algorithm development, hardware integration, and software systems. More notably, the team already has years of experience in the development of rehabilitation equipment and robots, providing a solid foundation for technological breakthroughs.
At the same time, Xiangyu Medical is also accelerating its layout in the AI domain. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from parsing structured medical records to generating personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a 99% risk prediction accuracy rate and a 45% reduction in missed diagnosis rates, marking a groundbreaking achievement. This accumulation of technology may lay the groundwork for the intelligent upgrade of medical robot products.
01
Having already secured a place in the rehabilitation medical device market, why has Xiangyu Medical chosen to make a high-profile entry into the robotics sector at this time? Behind this decision are three strategic considerations:
Currently, there is a prominent imbalance in the supply and demand of rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation doctors, and traditional equipment heavily relies on manual operation. Facing the personalized rehabilitation needs of complex patients such as those with stroke or post-orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, which not only alleviates the pressure of manpower shortages but also significantly improves treatment outcomes. Xiangyu Medical's choice to enter the robotics field through the rehabilitation scenario is a precise targeting of this essential market.
Additionally, the domestic rehabilitation equipment market is highly competitive with homogenized products, while medical robotics, as a
technical field, offers a unique opportunity for differentiation and innovation.Sure, please provide the content that needs to be translated. On February 26th, Shanghai-listed company Xiangyu Medical disclosed an important strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly garnered market attention, marking the formal entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. The expertise of the team covers core areas including mechanical design, algorithm development, hardware integration, and software systems. Notably, the team has years of experience in the development of rehabilitation equipment and robots, providing a solid foundation for technological breakthroughs. At the same time, Xiangyu Medical is also accelerating its layout in the AI domain. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from parsing structured medical records to generating personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a breakthrough with 99% risk prediction accuracy and a 45% reduction in missed diagnosis rates. This technological accumulation may lay the groundwork for the intelligent upgrade of medical robot products. 01 Xiangyu Medical, which has already secured a foothold in the rehabilitation medical device market, why choose to enter the robotics track at this moment? Behind this decision are three strategic considerations: Currently, there is a significant imbalance between supply and demand for rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation physicians. Moreover, traditional equipment heavily relies on manual operation. Facing the personalized rehabilitation needs of complex patients such as those with stroke or post-orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages and significantly improving treatment outcomes. Xiangyu Medical's choice to enter the robotics field through the rehabilitation scenario is a precise targeting of this high-demand market. In addition, the domestic rehabilitation equipment market is highly competitive with homogeneous products. Medical robotics, as a technology-intensive field, involves interdisciplinary innovation. By establishing an independent subsidiary, Xiangyu Medical aims to concentrate resources on overcoming core technologies such as motion control and human-robot interaction, dedicated to building a patent moat. Through the deployment
On February 26th, the STAR Market-listed company Xiangyu Medical disclosed an important strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the formal entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. The team covers core areas including mechanical design, algorithm development, hardware integration, and software systems. More notably, the team has years of experience in the development of rehabilitation equipment and robots, which provides a solid foundation for technological breakthroughs. At the same time, Xiangyu Medical's layout in the AI sector is also accelerating. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from structured analysis of medical records to the generation of personalized treatment plans. Its VTE (Venous Thromboembolism) intelligent prevention and control system has achieved a breakthrough result with 99% risk prediction accuracy and a 45% reduction in missed diagnosis rates. This accumulation of technology may lay the groundwork for the intelligent upgrade of medical robot products. 01 Having already established a presence in the rehabilitation medical device market, why did Xiangyu Medical choose to enter the robotics track at this time? Behind this decision lie three strategic considerations: Currently, the imbalance between supply and demand for rehabilitation medical resources in China is prominent, with a shortage of rehabilitation doctors reaching up to 300,000. Moreover, traditional equipment heavily relies on manual operation. In the face of complex patient needs such as post-stroke and post-orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, thereby alleviating the pressure of manpower shortages and significantly improving treatment outcomes. Xiangyu Medical’s choice to enter the robotics field through the rehabilitation scenario is a precise targeting of this essential market. Additionally, the domestic rehabilitation equipment market is highly competitive with homogenization. Medical robotics, as a technology-intensive field, involves interdisciplinary innovation. By establishing an independent subsidiary, Xiangyu Medical aims to concentrate resources on overcoming core technologies such as motion control and human-machine interaction, and is committed to building a patent moat. Through the deployment of AI large models, such as dynamic On February 26th, Xiangyu Medical, a company listed on the STAR Market, disclosed an important strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the formal entry of Xiangyu Medical, known for its rehabilitation medical equipment, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology, with expertise covering core areas like mechanical design, algorithm development, hardware integration, and software systems. More notably, the team already has years of experience in the development of rehabilitation equipment and robots, which provides a solid foundation for technological breakthroughs. At the same time, Xiangyu Medical is also accelerating its layout in the AI sector. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from structured parsing of medical records to the generation of personalized treatment plans. Its VTE (Venous Thromboembolism) intelligent prevention and control system has achieved a breakthrough result of 99% risk prediction accuracy and a 45% reduction in missed diagnosis rate. This accumulation of technology may lay the groundwork for the intelligent upgrade of medical robot products. 01 Having already established a foothold in the rehabilitation medical equipment market, why did Xiangyu Medical choose to enter the robotics track at this time? Behind this decision are three strategic considerations: Currently, there is a significant imbalance between supply and demand for rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation doctors, and traditional equipment heavily relies on manual operation. In the face of the personalized rehabilitation needs of complex patients such as those recovering from stroke or orthopedic surgery, traditional methods fall short. Medical robots, with the help of intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages while significantly improving treatment outcomes. By entering the robotics field through the rehabilitation scenario, Xiangyu Medical is precisely targeting this essential market. In addition, the domestic rehabilitation equipment market is highly competitive with homogenized products, while medical robotics, as a technology-intensive field, involves interdisciplinary innovation. Xiangyu Medical has established an independent subsidiary, concentrating resources to tackle core technologies such as motion control and human-robot interaction, aiming to build a patent moat. Through the deployment of large AI models, such as dynamic risk tracking and plan generation systems
On February 26, the STAR Market-listed company Xiangyu Medical disclosed a significant strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly garnered market attention, marking the formal entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. The expertise covers core areas including mechanical design, algorithm development, hardware integration, and software systems. Notably, the team already has years of experience in rehabilitation equipment and robotics development, providing a solid foundation for technological breakthroughs. Meanwhile, Xiangyu Medical is also accelerating its layout in the AI sector. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from parsing structured medical records to generating personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a breakthrough with 99% risk prediction accuracy and a 45% reduction in missed diagnoses. This technological accumulation may lay the groundwork for the intelligent upgrade of medical robot products. 01 Having already established a presence in the rehabilitation medical device market, why did Xiangyu Medical choose to make a high-profile entry into the robotics field at this time? There are three strategic considerations behind this decision: Currently, there is a significant imbalance between supply and demand for rehabilitation medical resources in China, with a shortage of over 300,000 rehabilitation physicians. Moreover, traditional equipment heavily relies on manual operation. In the face of complex patient needs, such as those recovering from stroke or orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages and significantly improving treatment outcomes. Xiangyu Medical's entry into the robotics field through the rehabilitation scenario is a precise targeting of this essential market. Additionally, the domestic rehabilitation device market is highly competitive with homogenized products. Medical robotics, as a technology-intensive field, involves interdisciplinary innovation. By establishing an independent subsidiary, Xiangyu Medical is concentrating resources to tackle core technologies such as motion control and human-robot interaction, aiming to build a patent moat. Through the deployment of AI large models, such as dynamic risk tracking and plan generation systems, the company aims to endow its robotic products with a "smart brain," moving beyond mere execution On February 26, Sci-Tech Innovation Board-listed company Xiangyu Medical disclosed in its investor relations activity record that it has made a significant strategic move: officially establishing a robotics subsidiary and successfully assembling a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the official entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, bringing together technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. The team covers core areas including mechanical design, algorithm development, hardware integration, and software systems. More notably, the team already has years of experience in rehabilitation equipment and robot development, providing a solid foundation for technological breakthroughs. At the same time, Xiangyu Medical is also accelerating its layout in the AI field. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from structured analysis of medical records to the generation of personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a breakthrough result with a 99% risk prediction accuracy rate and a 45% reduction in missed diagnosis rates. This technological accumulation may lay the groundwork for the intelligent upgrade of medical robot products. 01 Having already secured a place in the rehabilitation medical device market, why has Xiangyu Medical chosen to enter the robotics sector at this time? Behind this decision are three strategic considerations: Currently, there is a significant imbalance between the supply and demand for rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation physicians. Moreover, traditional equipment heavily relies on manual operation. In the face of complex patients with conditions such as stroke and post-orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages and significantly improving treatment outcomes. Xiangyu Medical's choice to enter the robotics field through the rehabilitation scenario is a precise targeting of this essential market. Additionally, the domestic rehabilitation equipment market is highly competitive with homogenized products. Medical robotics, as a technology-intensive field, involves interdisciplinary innovation. By establishing an independent subsidiary, Xiangyu Medical is concentrating its resources on overcoming core technologies such as motion control and human-robot interaction, aiming to build a patent moat. Through the deployment of AI large models, such as dynamic risk tracking and plan generation systems, it aims to equip robot products with a "smart brain," transforming them from mere "execution tools" to "decision assistants." On February 26, Shanghai-listed company Xiangyu Medical disclosed in its investor relations activity record that it has made a significant strategic move: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly garnered market attention, marking the entry of Xiangyu Medical, known for its rehabilitation medical devices, into the medical robotics field. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, bringing together technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology, with expertise covering core areas such as mechanical design, algorithm development, hardware integration, and software systems. More notably, the team already has years of experience in the development of rehabilitation equipment and robots, providing a solid foundation for technological breakthroughs. At the same time, Xiangyu Medical is also accelerating its layout in the AI sector. The company has completed the localization deployment and secondary training of open-source large models and plans to deeply integrate AI technology into medical scenarios—from structured analysis of medical records to the generation of personalized treatment plans. Its VTE (Venous Thromboembolism) intelligent prevention and control system has achieved a breakthrough result of 99% risk prediction accuracy and a 45% reduction in missed diagnosis rates. This accumulation of technology may lay the groundwork for the intelligent upgrade of medical robot products. 01 Having already secured a foothold in the rehabilitation medical device market, why did Xiangyu Medical choose to enter the robotics track at this time? There are three strategic considerations behind this decision: Currently, there is a significant imbalance between the supply and demand for rehabilitation medical resources in China, with a shortage of over 300,000 rehabilitation physicians. Additionally, traditional equipment heavily relies on manual operation. In the face of the personalized rehabilitation needs of complex patients such as those recovering from stroke or orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, which not only alleviates the pressure of manpower shortages but also significantly improves treatment outcomes. Xiangyu Medical's choice to enter the robotics field from the rehabilitation perspective is a precise targeting of this essential market. Moreover, the domestic rehabilitation equipment market is highly competitive with homogenized products, while medical robotics is a technology-intensive field involving interdisciplinary innovation. By establishing an independent subsidiary, Xiangyu Medical is focusing its resources on overcoming core technologies such as motion control and human-robot interaction, aiming to build a patent moat. Through the deployment of AI large models, such as dynamic risk tracking and plan generation systems, it aims to endow robotic products with a "smart brain," transforming them from mere "execution tools" to "decision assistants." Policy and capitalSure, please provide the content that needs to be translated. On February 26th, Sci-Tech Innovation Board listed company Xiangyu Medical disclosed an important strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the formal entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. The team covers core areas including mechanical design, algorithm development, hardware integration, and software systems. Notably, the team has years of experience in rehabilitation equipment and robotics development, providing a solid foundation for technological breakthroughs. At the same time, Xiangyu Medical is also accelerating its layout in the AI field. The company has completed the localization deployment and secondary training of open-source large models, and plans to deeply integrate AI technology into medical scenarios—from structured analysis of medical records to the generation of personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a 99% risk prediction accuracy rate and a 45% reduction in missed diagnosis rates. This technological accumulation may pave the way for the intelligent upgrade of medical robot products. 01 Xiangyu Medical, which has already established itself in the rehabilitation medical device market, why choose to enter the robotics track at this time? Behind this decision lie three strategic considerations: Currently, there is a significant imbalance between supply and demand for rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation physicians. Additionally, traditional equipment heavily relies on manual operation. In the face of complex patient needs, such as those recovering from stroke or orthopedic surgery, traditional methods are inadequate. Medical robots, utilizing intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages and significantly improving treatment outcomes. By entering the robotics field through the rehabilitation sector, Xiangyu Medical is precisely targeting this high-demand market. Moreover, the domestic rehabilitation equipment market is highly competitive with homogenization. Medical robotics, as a technology-intensive field, involves interdisciplinary innovation. Xiangyu Medical has established an independent subsidiary to focus on core technologies such as motion control and human-robot interaction, aiming to build a patent moat. By deploying AI large models, such as dynamic risk tracking and plan generation systems, the company aims to endow robotic products with a "smart brain," transforming them from mere "execution tools" to "decision assistants." The dual drivers of policy and capital are also key factors in Xiangyu Medical's entry. In 2023, the Ministry of Industry and Information Technology and other departmentsSure, please provide the content that needs to be translated. On February 26th, Xiangyu Medical, a company listed on the STAR Market, disclosed an important strategic move in its investor relations activity record: the official establishment of a robotics subsidiary and the successful assembly of a nearly 100-person robotics R&D center. This news quickly garnered market attention, marking Xiangyu Medical, known for rehabilitation medical devices, officially entering the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology, with expertise covering core areas like mechanical design, algorithm development, hardware integration, and software systems. More notably, the team has years of experience in the development of rehabilitation equipment and robots, providing a solid foundation for technological breakthroughs. Meanwhile, Xiangyu Medical is also accelerating its layout in the AI sector. The company has completed the localization deployment and secondary training of open-source large models, and plans to deeply integrate AI technology into medical scenarios—from structured analysis of medical records to the generation of personalized treatment plans. Its VTE (Venous Thromboembolism) intelligent prevention and control system has achieved a breakthrough result with 99% risk prediction accuracy and a 45% reduction in missed diagnosis rate. This accumulation of technology may pave the way for the intelligent upgrade of medical robot products. 01 Having already established a presence in the rehabilitation medical device market, why did Xiangyu Medical choose to make a high-profile entry into the robotics arena at this time? There are three underlying strategic considerations: Currently, there is a significant imbalance between the supply and demand for rehabilitation medical resources in China, with a shortage of 300,000 rehabilitation physicians. Additionally, traditional equipment heavily relies on manual operation. In the face of complex patients, such as those recovering from stroke or orthopedic surgery, traditional methods fall short. Medical robots, leveraging intelligent algorithms, can precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages while significantly improving treatment outcomes. Xiangyu Medical's entry into the robotics field through the rehabilitation scenario is a precise targeting of this essential market. Furthermore, the domestic rehabilitation equipment market is highly competitive with homogeneous products. Medical robotics, as a technology-intensive field, involves interdisciplinary innovation. By establishing an independent subsidiary, Xiangyu Medical aims to concentrate resources on overcoming core technologies such as motion control and human-robot interaction, dedicated to building a patent moat. Through the deployment of AI large models, such as dynamic risk tracking and plan generation systems, the company aims to endow robotic products with a "smart brain," transforming them from mere "execution tools" to "decision-making assistants." The dual drivers of policy and capital are also key factors in Xiangyu Medical's entry. In 2023, the Ministry of Industry and Information Technology and 16 other departments jointly issued the "Robotics + Application Action Plan Implementation Scheme," clearly listing medical applications as a priority. On February 26, Sci-Tech Innovation Board listed company Xiangyu Medical disclosed in its investor relations activity record an important strategic move: the official establishment of a robotics subsidiary and the successful formation of a nearly 100-person robotics R&D center. This news quickly attracted market attention, marking the formal entry of Xiangyu Medical, known for its rehabilitation medical devices, into the field of medical robotics. According to the disclosed information, Xiangyu Medical's robotics R&D team is based in Shanghai, Zhengzhou, and Anyang headquarters, gathering technical talents from top domestic and international universities such as Fudan University, Shanghai Jiao Tong University, and Harbin Institute of Technology. Their expertise covers core areas including mechanical design, algorithm development, hardware integration, and software systems. Notably, the team already has years of experience in the development of rehabilitation equipment and robots, providing a solid foundation for technological breakthroughs. Meanwhile, Xiangyu Medical is also accelerating its layout in the AI sector. The company has completed the localization deployment and secondary training of open-source large models, and plans to deeply integrate AI technology into medical scenarios—from parsing structured medical records to generating personalized treatment plans. Its VTE (venous thromboembolism) intelligent prevention and control system has achieved a groundbreaking result with 99% risk prediction accuracy and a 45% reduction in missed diagnosis rate. This technological accumulation may set the stage for the intelligent upgrade of medical robot products. 01 Having already secured a foothold in the rehabilitation medical equipment market, why has Xiangyu Medical chosen this moment to make a high-profile entry into the robotics sector? The move is underpinned by three strategic considerations: Currently, there is a significant imbalance between supply and demand for rehabilitation medical resources in our country, with a shortage of 300,000 rehabilitation physicians. Moreover, traditional equipment heavily relies on manual operation. In the face of personalized rehabilitation needs for complex patients, such as those recovering from stroke or orthopedic surgery, traditional methods fall short. Medical robots, however, leverage intelligent algorithms to precisely control movements and provide real-time feedback, alleviating the pressure of manpower shortages while significantly improving treatment outcomes. Xiangyu Medical's decision to enter the robotics field through the rehabilitation scenario is undoubtedly a precise targeting of this essential market. In addition, the domestic rehabilitation equipment market is characterized by intense homogeneous competition, whereas medical robotics, as a technology-intensive field, involves interdisciplinary innovation. Xiangyu Medical has established an independent subsidiary to concentrate resources on overcoming core technologies such as motion control and human-robot interaction, aiming to build a patent moat. By deploying AI large models, such as dynamic risk tracking and plan generation systems, it endows its robotic products with a "smart brain," transforming them from mere "execution tools" to "decision-making assistants." The dual drivers of policy and capital are also important factors for Xiangyu Medical to enter the market. In 2023, the Ministry of Industry and Information Technology and 16 other departments jointly issued the "Robotics + Application Action Plan", clearly identifying healthcare as a key area for robotics applications. Beijing, Shanghai, and other places have introduced special subsidy policies, with individual medical robot projects receiving up to ten million yuan in rewards. In the capital market, the financing enthusiasm for the medical robotics sector continues to rise, with more than 30 related financing events in China in 2023, and the highest single amount reaching 1.5 billion yuan. By entering this field at this time, Xiangyu Medical can fully enjoy the policy benefits and create favorable conditions for future spin-off financing. 02 Behind the 50% decline in net profit: Behind the 50% decline in net profit: Behind the 50% decline in net profit: It is noteworthy that Xiangyu Medical's 2023 financial report shows a 49.72% year-on-year decline in its net profit attributable to shareholders. From the details of the financial report, the decline in net profit mainly stems from two pressures: Cyclical industry adjustment: In 2023, the financial pressure on public hospitals increased, leading to delays in some rehabilitation equipment procurement projects; Surge in R&D investment: The company's R&D expenses increased by 37% year-over-year, with a significant increase in the proportion allocated to new directions such as robotics and AI; Despite short-term pressures, the logic of strategic transformation is clear: R&D investment transformed into technological reserves: By the end of 2023, Xiangyu Medical added 152 new patents, 15% of which are related to robotic technologies; Optimization of order structure: The robot subsidiary has signed pilot agreements with multiple top-tier hospitals, with unit prices 3-5 times higher than traditional equipment; Policy subsidies offset costs: In 2023, the company received 120 million yuan in government grants, an increase of 68% year-over-year, partially covering R&D expenditures. It can be seen that the decline in net profit is more a phased manifestation during the period of strategic investment. As robotic products enter the commercialization stage, their high-margin characteristics (with gross margins for medical robots generally exceeding 60%) are expected to become a new source of profit growth. 03 The Positioning Battle in the Robot Track of Domestic Medical Device Enterprises Xiangyu Medical is not alone. With the acceleration of aging and the promotion of domestic substitution policies for surgical robots, major domestic medical device companies have already sparked a wave of layout in the medical robot sector: MicroPort: Its subsidiary MicroPort Robotics listed on the Hong Kong Stock Exchange, with the Toumai laparoscopic surgical robot completing over ten thousand clinical cases; Weigao Group: Collaborated with Tianjin University to develop orthopedic surgery robots, approved as national innovative medical devices; United Imaging: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; Tinavi: Focused on orthopedic navigation robots, with a market share exceeding 75%. Compared to these companies, Xiangyu Medical chose a differentiated path—focusing on rehabilitation scenarios and avoiding the "red ocean competition" of surgical robots. Leveraging its existing rehabilitation equipment channels, Xiangyu Medical was able to quickly expand its market, while integrating AI diagnostic data with robotic training loops to build a rehabilitation effectiveness
Cyclical industry adjustment: In 2023, the financial pressure on public hospitals increased, leading to delays in some rehabilitation equipment procurement projects; Surge in R&D investment: The company's R&D expenses rose by 37% year-on-year, with a significant increase in the proportion allocated to new directions such as robotics and AI; Cyclical industry adjustment: In 2023, the financial pressure on public hospitals increased, leading to delays in some rehabilitation equipment procurement projects; Surge in R&D investment: The company's R&D expenses rose by 37% year-on-year, with a significant increase in the proportion allocated to new directions such as robotics and AI; Cyclical industry adjustment: In 2023, the financial pressure on public hospitals increased, leading to delays in some rehabilitation equipment procurement projects; Cyclical industry adjustment: In 2023, the financial pressure on public hospitals increased, leading to delays in some rehabilitation equipment procurement projects; Surge in R&D investment: The company's R&D expenses rose by 37% year-on-year, with a significant increase in the proportion allocated to new directions such as robotics and AI; Surge in R&D investment: The company's R&D expenses rose by 37% year-on-year, with a significant increase in the proportion allocated to new directions such as robotics and AI; Despite short-term pressures, the logic of strategic transformation is clearly visible: Transformation of R&D investment into technological reserves: By the end of 2023, Xiangyu Medical added 152 new patents, with 15% related to robot technologies; Optimization of order structure: The robotics subsidiary has signed pilot agreements with multiple top-tier hospitals, with the unit price being 3-5 times higher than traditional equipment; Policy subsidies offset costs: In 2023, the company received 1.2 billion yuan in government grants, an increase of 68% year-on-year, partially covering R&D expenses. It can be seen that the decline in net profit is more a temporary manifestation during the strategic investment phase. As robotic products enter the commercialization stage, their high-margin characteristics (medical robots generally have a gross margin exceeding 60%) are expected to become a new source of profit growth. 03 The Positioning Battle in the Robot Sector for Domestic Medical Device Enterprises Xiangyu Medical is not an isolated case. Under the acceleration of aging and the promotion of policies supporting domestic substitution of surgical robots, major domestic medical device companies have launched a craze for medical robot layouts: MicroPort: Its MicroPort Robotics listed on the Hong Kong Stock Exchange, with the Toumai laparoscopic surgery robot completing over ten thousand clinical cases; Weigao Group: Collaborated with Tianjin University to develop orthopedic surgery robots, which have been approved as national innovative medical devices; United Imaging Healthcare: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; Tinavi: Specializes in orthopedic navigation robots, with a market share exceeding 75%. In comparison with these enterprises, Xiangyu Medical has chosen a differentiated path—focusing on rehabilitation scenarios, avoiding the "red ocean competition" of surgical robots. Leveraging its existing rehabilitation equipment channels, Xiangyu Medical was able to quickly expand its market. At the same time, it combines AI diagnostic data with robot training loops to build a rehabilitation outcome evaluation system. Through a "device + service" model, it has created a post-hospital home rehabilitation robot ecosystem, forging a unique and distinctive development path. 04 Conversion of R&D investment into technological reserves: By the end of 2023, Xiangyu Medical added 152 new patents, 15% of which are related to robot technology; Optimization of order structure: The robot subsidiary has signed pilot agreements with multiple top-tier hospitals, increasing the unit price by 3-5 times compared to traditional equipment; Policy subsidies offset costs: In 2023, the company received government grants of 120 million yuan, an increase of 68% year-on-year, partially covering R&D expenses. Conversion of R&D investment into technological reserves: By the end of 2023, Xiangyu Medical added 152 new patents, 15% of which are related to robot technology; Optimization of order structure: The robot subsidiary has signed pilot agreements with multiple top-tier hospitals, increasing the unit price by 3-5 times compared to traditional equipment; Policy subsidies offset costs: In 2023, the company received government grants of 120 million yuan, an increase of 68% year-on-year, partially covering R&D expenses. Conversion of R&D investment into technological reserves: By the end of 2023, Xiangyu Medical added 152 new patents, 15% of which are related to robot technology; Conversion of R&D investment into technological reserves: By the end of 2023, Xiangyu Medical added 152 new patents, 15% of which are related to robot technology; Optimization of order structure: The robot subsidiary has signed pilot agreements with multiple top-tier hospitals, increasing the unit price by 3-5 times compared to traditional equipment; Optimization of order structure: The robot subsidiary has signed pilot agreements with multiple top-tier hospitals, increasing the unit price by 3-5 times compared to traditional equipment; Policy subsidies offset costs: In 2023, the company received government grants of 120 million yuan, an increase of 68% year-on-year, partially covering R&D expenses. Policy subsidies offset costs: In 2023, the company received government grants of 120 million yuan, an increase of 68% year-on-year, partially covering R&D expenses. It can be seen that the decline in net profit is more of a phased manifestation during the period of strategic investment. As robot products enter the commercialization stage, their high gross margin characteristics (with medical robots generally having a gross margin exceeding 60%) are expected to become a new source of profit growth. 03 The Positioning Battle of Domestic Medical Device Enterprises in the Robot Track The Positioning Battle of Domestic Medical Device Enterprises in the Robot Track The Positioning Battle of Domestic Medical Device Enterprises in the Robot Track Xiangyu Medical is not an isolated case. Driven by the acceleration of aging and policies promoting domestic substitution for surgical robots, domestic medical device giants have already sparked a wave of layout in medical robots: MicroPort: Its subsidiary MicroPort Robotics has listed on the Hong Kong Stock Exchange, with the Toumai laparoscopic surgical robot completing over ten thousand clinical cases; Weigao Group: Collaborated with Tianjin University to develop an orthopedic surgery robot, which has been approved as a national innovative medical device; United Imaging Healthcare: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; Tinavi Medical: Specializes in orthopedic navigation robots, with a market share exceeding 75%. In comparison to these companies, Xiangyu Medical has chosen a differentiated path—focusing on rehabilitation scenarios and avoiding the "red ocean competition" of surgical robots. Leveraging its existing channels for rehabilitation equipment, Xiangyu Medical was able to quickly expand its market. At the same time, by integrating AI diagnostic data with robot training loops, it has established a rehabilitation efficacy evaluation system. Through a "device + service" model, Xiangyu Medical has created a post-hospital home rehabilitation robot ecosystem, forging a unique and distinctive path of differentiated development. 04 Frost & Sullivan predicts that China's medical robot market size will grow from 9.3 billion yuan in 2023 to a trillion-level by 2030, with a compound annual growth rate of 30.2%. Currently, three key trends are profoundly reshaping the industry landscape. The pace of technological integration is accelerating, with the deep combination of AI and 5G creating new scenarios for telemedicine. With the widespread coverage of 5G networks and the increasing maturity of edge computing technology, medical robots can break through spatial limitations. For example, doctors can use remote control robots to provide precise guidance for surgeries at grassroots hospitals; wearable robots can also collect real-time rehabilitation data from home patients, providing strong support for the continuity of medical services. Specialization and popularization are advancing simultaneously. In the high-end sector, specialized robots in neurosurgery and interventional oncology are continuously making new breakthroughs; in the grassroots market, rehabilitation robots priced below 500,000 yuan are experiencing rapid growth. At the policy level, DRG/DIP payment reforms are encouraging hospitals to preferentially purchase cost-effective domestic equipment, providing broad space for the development of domestically produced medical robots. The ethical and regulatory systems are also continuously improving. The National Medical Products Administration (NMPA) has issued the "Guiding Principles for the Registration Review of Artificial Intelligence Medical Devices," setting clear requirements for algorithm traceability and data security. In the future, the clinical validation standards and liability determination rules for medical robots will be gradually improved, safeguarding the healthy development of the industry. The robotics subsidiary of Xiangyu Medical is both a strategic move for the company to break through growth bottlenecks and
MicroPort: Its subsidiary MicroPort Robotics has listed on the Hong Kong Stock Exchange, and the Toumai laparoscopic surgical robot has completed over 10,000 clinical cases; Weigao Group: Collaborated with Tianjin University to develop an orthopedic surgery robot, which was approved as a national innovative medical device; United Imaging Healthcare: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; Tinavi Medical Technologies: Focused on orthopedic navigation robots, with a market share exceeding 75%. MicroPort: Its subsidiary MicroPort Robotics has listed on the Hong Kong Stock Exchange, and the Toumai laparoscopic surgical robot has completed over 10,000 clinical cases; Weigao Group: Collaborated with Tianjin University to develop an orthopedic surgery robot, which was approved as a national innovative medical device; United Imaging Healthcare: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; Tinavi Medical Technologies: Focused on orthopedic navigation robots, with a market share exceeding 75%. MicroPort: Its subsidiary MicroPort Robotics has listed on the Hong Kong Stock Exchange, and the Toumai laparoscopic surgical robot has completed over 10,000 clinical cases; MicroPort: Its subsidiary MicroPort Robotics has listed on the Hong Kong Stock Exchange, and the Toumai laparoscopic surgical robot has completed over 10,000 clinical cases; Weigao Group: Collaborated with Tianjin University to develop an orthopedic surgery robot, which was approved as a national innovative medical device; Weigao Group: Collaborated with Tianjin University to develop an orthopedic surgery robot, which was approved as a national innovative medical device; United Imaging Healthcare: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; United Imaging Healthcare: Launched the uRT-ART radiotherapy robot, achieving sub-millimeter precise positioning; Tinavi Medical Technologies: Focused on orthopedic navigation robots, with a market share exceeding 75%. Tinavi Medical Technologies: Focused on orthopedic navigation robots, with a market share exceeding 75%. Compared to these companies, Xiangyu Medical chose a differentiated path — focusing on rehabilitation scenarios, avoiding the "red ocean" competition of surgical robots. Leveraging its existing rehabilitation equipment channels, Xiangyu Medical was able to quickly expand its market. Additionally, by integrating AI diagnostic data with robot training in a closed loop, it built a rehabilitation outcome evaluation system. Through the "equipment + service" model, Xiangyu Medical created a post-hospital home re
【Copyright and Disclaimer】The above information is collected and organized by PlastMatch. The copyright belongs to the original author. This article is reprinted for the purpose of providing more information, and it does not imply that PlastMatch endorses the views expressed in the article or guarantees its accuracy. If there are any errors in the source attribution or if your legitimate rights have been infringed, please contact us, and we will promptly correct or remove the content. If other media, websites, or individuals use the aforementioned content, they must clearly indicate the original source and origin of the work and assume legal responsibility on their own.
Most Popular
-
South Korea Extends Anti-Dumping Duties on Chinese Polypropylene Films for 5 Years with a Maximum Rate of 25.04%
-
Tariffs, Warm Weather Weigh on US Output
-
TCL Electronics Achieves a "Strong Start" in 2025 with Dual Growth in Global TV Shipments and Revenue in First Quarter
-
Medical Device Giants Maintain Strong M&A Enthusiasm: Key Sectors to Watch
-
ABB Completes Acquisition of Siemens' Switch Socket Business in China
